(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Passage Bio's earnings in 2026 is -$37,676,000.On average, 7 Wall Street analysts forecast PASG's earnings for 2026 to be -$30,141,224, with the lowest PASG earnings forecast at -$44,262,646, and the highest PASG earnings forecast at -$16,403,136. On average, 6 Wall Street analysts forecast PASG's earnings for 2027 to be -$25,644,195, with the lowest PASG earnings forecast at -$36,309,201, and the highest PASG earnings forecast at -$7,612,133.
In 2028, PASG is forecast to generate -$21,693,136 in earnings, with the lowest earnings forecast at -$29,456,036 and the highest earnings forecast at -$5,557,531.